Syntara Limited PXS.AX Stock
Syntara Limited Price Chart
Syntara Limited PXS.AX Financial and Trading Overview
| Syntara Limited stock price | 0.03 AUD |
| Previous Close | 0.05 AUD |
| Open | 0.05 AUD |
| Bid | 0.05 AUD x N/A |
| Ask | 0.05 AUD x N/A |
| Day's Range | 0.05 - 0.05 AUD |
| 52 Week Range | 0.04 - 0.09 AUD |
| Volume | 239.59K AUD |
| Avg. Volume | 381.1K AUD |
| Market Cap | 35.98M AUD |
| Beta (5Y Monthly) | 0.630268 |
| PE Ratio (TTM) | 5 |
| EPS (TTM) | 0 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.17 AUD |
PXS.AX Valuation Measures
| Enterprise Value | 20.53M AUD |
| Trailing P/E | 5 |
| Forward P/E | -5 |
| PEG Ratio (5 yr expected) | 0.16 |
| Price/Sales (ttm) | 2.1989489 |
| Price/Book (mrq) | 2.2727273 |
| Enterprise Value/Revenue | 1.255 |
| Enterprise Value/EBITDA | -2.144 |
Trading Information
Syntara Limited Stock Price History
| Beta (5Y Monthly) | 0.630268 |
| 52-Week Change | -36.48% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.09 AUD |
| 52 Week Low | 0.04 AUD |
| 50-Day Moving Average | 0.05 AUD |
| 200-Day Moving Average | 0.06 AUD |
PXS.AX Share Statistics
| Avg. Volume (3 month) | 381.1K AUD |
| Avg. Daily Volume (10-Days) | 213.16K AUD |
| Shares Outstanding | 719.52M |
| Float | 331.34M |
| Short Ratio | N/A |
| % Held by Insiders | 17.32% |
| % Held by Institutions | 37.48% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 12.30% |
| Operating Margin (ttm) | -76.15% |
| Gross Margin | 47.43% |
| EBITDA Margin | -58.55% |
Management Effectiveness
| Return on Assets (ttm) | -23.82% |
| Return on Equity (ttm) | 20.98% |
Income Statement
| Revenue (ttm) | 16.36M AUD |
| Revenue Per Share (ttm) | 0.03 AUD |
| Quarterly Revenue Growth (yoy) | -62.10% |
| Gross Profit (ttm) | 5.8M AUD |
| EBITDA | -9580000 AUD |
| Net Income Avi to Common (ttm) | 2.01M AUD |
| Diluted EPS (ttm) | 0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 16.45M AUD |
| Total Cash Per Share (mrq) | 0.02 AUD |
| Total Debt (mrq) | 3.19M AUD |
| Total Debt/Equity (mrq) | 20.41 AUD |
| Current Ratio (mrq) | 3.307 |
| Book Value Per Share (mrq) | 0.022 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11478000 AUD |
| Levered Free Cash Flow (ttm) | -8637375 AUD |
Profile of Syntara Limited
| Country | Australia |
| State | NSW |
| City | Frenchs Forest |
| Address | 20 Rodborough Road |
| ZIP | 2086 |
| Phone | 61 2 9454 7200 |
| Website | https://www.pharmaxis.com.au |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 69 |
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Q&A For Syntara Limited Stock
What is a current PXS.AX stock price?
Syntara Limited PXS.AX stock price today per share is 0.03 AUD.
How to purchase Syntara Limited stock?
You can buy PXS.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Syntara Limited?
The stock symbol or ticker of Syntara Limited is PXS.AX.
Which industry does the Syntara Limited company belong to?
The Syntara Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Syntara Limited have in circulation?
The max supply of Syntara Limited shares is 722.61M.
What is Syntara Limited Price to Earnings Ratio (PE Ratio)?
Syntara Limited PE Ratio is 0.00000000 now.
What was Syntara Limited earnings per share over the trailing 12 months (TTM)?
Syntara Limited EPS is 0 AUD over the trailing 12 months.
Which sector does the Syntara Limited company belong to?
The Syntara Limited sector is Healthcare.